Phase 3 N=12 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia
Familial Dysautonomia
Primary: Composite Daily Score — 6.9; 9.7 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
Stage I Bladder Cancer · Stage II Bladder Cancer · Stage III Bladder Cancer
Primary: Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive…
Phase 2 N=49 Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
Alzheimer's Disease · Cognitive Impairment
Primary: Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) — -3.40; -1.07; -7.58; -3.09 SUVBSA2
Phase 3 N=268 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Systemic Lupus Erythematosus
Primary: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) — 267; 260; 235; 206 Participants
Phase 2 N=51 Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome · Acute Myeloid Leukemia
Primary: Phase I: Recommended Phase II Dose — 20 mg/day
N/A N=420 Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Malignant Melanoma
Primary: BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories — 150; 143; 264; 266 number of samples
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
Phase 1 N=48 A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 2 N=52 An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
Soft Tissue Sarcoma
Primary: Progression-free Rate at 12 Weeks (PFR12wks) — 60.0; 31.3 Percentage of participants
N/A N=82 Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women
Pain
Primary: Patient Perceived Pain on a 100-point Visual Analogue Scale. — 0.5; 0.8; 5.8; 5.9 units on a scale
Phase 3 N=28 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
Rheumatoid Arthritis
Primary: Disease Activity as Measured by Disease Activity Score 28 (DAS28) — 5.4; 3.5; 2.8; 2.2 units on a scale
N/A N=347 An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) — 0.8; 3.7…
N/A N=185 An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Anemia, Kidney Disease, Chronic
Primary: Number of Participants With Adverse Events (AEs) — 49; 22 participants
Phase 2 N=9 Research Study of Treatment for Winter Depression With Different Colors of Light
Seasonal Affective Disorder
Primary: Structured Interview Guide for the Hamilton Depression Scale - Seasonal Affective Disorder Version (SIGH-SAD); Weekly for Three Weeks — 16.3; 8 units on a scale
N/A N=37 Comparison of Airway Intubation Devices When Using a Biohazard Suit
Intubation; Difficult
Primary: Time to Successful Intubation — 54; 106.5; 66; 83.5 seconds